An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia
Study sponsor: BioXcel Therapeutics Inc
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-04-01Actual
Enrollment · participants5Actual
Source updated2026-08-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.